← Back to Search

Procedure

MRI for Glioblastoma

N/A
Recruiting
Led By Benjamin M Ellingson
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients > 18 years of age
Patients with newly diagnosed, suspected or recurrent glioblastoma (GBM) patients with enhancing tumors greater than 1.5 mL clinically indicated for surgical resection. Recurrent GBM must have occurred more than 3 months after the end of radiation therapy per Response Assessment in Neuro-Oncology Criteria (RANO) guidelines
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial uses MRI scans to study brain tumor biology in people with glioblastoma that can be surgically removed. It aims to find out which patients will benefit from a drug therapy to treat the cancer.

Who is the study for?
This trial is for adults over 18 with new or returning glioblastoma, a type of brain tumor. Participants must have tumors larger than 1.5 mL that can be surgically removed and should not have had radiation therapy within the last three months.
What is being tested?
The study uses MRI scans to understand brain tumor biology in glioblastoma patients eligible for surgery. It aims to find out which patients might benefit from a drug called bevacizumab by analyzing MRI images and biomarkers.
What are the potential side effects?
Since this trial involves MRI scans and biospecimen collection rather than testing new drugs, side effects are minimal but may include discomfort during imaging or at the biospecimen collection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I have a glioblastoma larger than 1.5 mL and need surgery, or my glioblastoma has recurred 3 months after radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
DCN expression among Mesenchymal-Like (MES-like) cells
DCN expression correlated to ADCL
Decorin (DCN) expression
+1 more
Secondary study objectives
DCN protein concentration in blood plasma

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Screening (MRI)Experimental Treatment3 Interventions
Patients undergo one MRI scan over approximately 1 hour prior to surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Biospecimen Collection
2004
Completed Phase 3
~2020

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,928 Previous Clinical Trials
41,018,010 Total Patients Enrolled
330 Trials studying Glioblastoma
23,326 Patients Enrolled for Glioblastoma
Jonsson Comprehensive Cancer CenterLead Sponsor
370 Previous Clinical Trials
35,144 Total Patients Enrolled
18 Trials studying Glioblastoma
500 Patients Enrolled for Glioblastoma
Benjamin M EllingsonPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
2 Previous Clinical Trials
68 Total Patients Enrolled
~23 spots leftby Apr 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top